TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind,Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneously Administered REGN727 in Healthy Volunteers
Brief Summary: This study will test the safety and tolerability (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in healthy subjects. The study drug and placebo will be administered by an injection under the skin at one clinic visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs (blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.


Options:
A: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind,Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneously Administered REGN727 in Healthy Volunteers
Brief Summary: This study will test the safety and tolerability (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in healthy subjects. The study drug and placebo will be administered by an injection under the skin at one clinic visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs (blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4
B: Arm Label: bococizumab (PF-04950615); Type: EXPERIMENTAL; Interventions: Drug: bococizumab (PF-04950615) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bococizumab (PF-04950615); Assigned to Arm(s): bococizumab (PF-04950615) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: bococizumab (PF-04950615); Type: EXPERIMENTAL; Interventions: Drug: bococizumab (PF-04950615) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bococizumab (PF-04950615); Assigned to Arm(s): bococizumab (PF-04950615) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine if memantine is effective in the treatment on cognitive disorders of Relapsing - Remitting multiple sclerosis. m


Options:
A: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
B: Arm Label: Galantamine and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Galantamine CR, Drug: Placebo | Arm Label: Galantamine and Memantine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine CR, Drug: Memantine | Intervention Type: DRUG; Name: Galantamine CR; Assigned to Arm(s): Galantamine and Memantine, Galantamine and Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Galantamine and Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Galantamine and Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Diabetes Care in General Practice Study: Randomised Controlled Trial of Structured Personal Care of Type 2 Diabetes Mellitus
Brief Summary: The aims of a concluding 14-year follow-up study are:

* To investigate what long-term effect the project model for structured, personalized diabetes care has on 1) the patients' mortality and development of diabetic complications, 2) the patients' use of services from the primary and secondary sector, 3) the patients' self-rated health and motivation, and 4) the doctor-patient relationship.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Peer-led Support Group, Other: Behavioral Health Consult, Other: Medication Therapy Management Consult, Other: La Cocina Alegre/ The Happy Kitchen, Other: Mind, Exercise, Nutrition, Do it! | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Peer-led Support Group; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Behavioral Health Consult; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Medication Therapy Management Consult; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: La Cocina Alegre/ The Happy Kitchen; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Mind, Exercise, Nutrition, Do it!; Assigned to Arm(s): Intervention
B: Arm Label: Information on community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Worker services; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker (CHW) services | Intervention Type: BEHAVIORAL; Name: Community Health Worker (CHW) services; Assigned to Arm(s): Community Health Worker services
C: Arm Label: Telemedical Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedical coaching, Other: Telemedicine | Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedical coaching | Intervention Type: BEHAVIORAL; Name: Telemedical coaching; Assigned to Arm(s): Telemedical Coaching, Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedical Coaching
D: Arm Label: Routine general practice care; Type: NO_INTERVENTION; Interventions: Behavioral: Structured personal care | Intervention Type: BEHAVIORAL; Name: Structured personal care; Assigned to Arm(s): Routine general practice care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border
Brief Summary: This is a randomised open label trial with follow up for 1 year. 660 adults and children above 6 months diagnosed with acute Plasmodium vivax will be randomised into 3 groups, either chloroquine, artesunate, or chloroquine/primaquine therapy. Participants will be screened on the day of inclusion then followed weekly for 8 visits and every 4 weeks until week 52. The primary objective of the study is to compare the efficacy of the WHO and Thai Ministry of Public Health recommended radical curative regimen of chloroquine and primaquine with the currently used monotherapy regimens of chloroquine and artesunate along the Thai-Burmese border.


Options:
A: Arm Label: Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine
B: Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Arm Label: Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine/Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine/Primaquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine | Intervention Type: DRUG; Name: Chloroquine/Primaquine; Assigned to Arm(s): Chloroquine/Primaquine
C: Arm Label: Cohort 1 Tafenoquine; Type: EXPERIMENTAL; Interventions: Drug: Tafenoquine | Arm Label: Cohort 1-Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine + Primaquine | Arm Label: Cohort 2 Tafenoquine; Type: EXPERIMENTAL; Interventions: Drug: tafenoquine | Arm Label: Cohort 2 Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine + Primaquine | Intervention Type: DRUG; Name: Tafenoquine; Assigned to Arm(s): Cohort 1 Tafenoquine | Intervention Type: DRUG; Name: Chloroquine + Primaquine; Assigned to Arm(s): Cohort 1-Chloroquine | Intervention Type: DRUG; Name: tafenoquine; Assigned to Arm(s): Cohort 2 Tafenoquine | Intervention Type: DRUG; Name: Chloroquine + Primaquine; Assigned to Arm(s): Cohort 2 Chloroquine
D: Arm Label: DHA-P 7 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: DHA-P 14 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: Chloroquine 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine 14 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 7 days | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 14 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 7 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 14 days

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis
Brief Summary: The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to standard initiation of ART started as an outpatient.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Sertraline 400mg; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline 400mg
C: Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Arm Label: Fluconazole Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Arm Label: Fluconazole High Dose; Type: EXPERIMENTAL; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): Fluconazole High Dose, Fluconazole Low Dose, Standard Therapy | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): Fluconazole High Dose, Fluconazole Low Dose, Standard Therapy
D: Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis
Brief Summary: The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to standard initiation of ART started as an outpatient.


Options:
A: Arm Label: Early ART; Type: EXPERIMENTAL; Interventions: Drug: All licensed antiretroviral medications | Arm Label: Deferred ART; Type: ACTIVE_COMPARATOR; Interventions: Drug: All licensed antiretroviral medications | Intervention Type: DRUG; Name: All licensed antiretroviral medications; Assigned to Arm(s): Deferred ART, Early ART
B: Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy
C: Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis
Brief Summary: The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to standard initiation of ART started as an outpatient.


Options:
A: Arm Label: Immediate ART; Type: EXPERIMENTAL; Interventions: Other: Strategy: Immediate ART | Arm Label: Deferred ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Strategy: Deferred ART | Intervention Type: OTHER; Name: Strategy: Immediate ART; Assigned to Arm(s): Immediate ART | Intervention Type: OTHER; Name: Strategy: Deferred ART; Assigned to Arm(s): Deferred ART
B: Arm Label: Combination intervention + incentives; Type: EXPERIMENTAL; Interventions: Other: Point of care CD4+ after HIV diagnosis, Other: Accelerated ART initiation, Behavioral: SMS appointment reminders, Other: Non-cash Financial Incentives | Arm Label: Combination intervention strategy(CIS); Type: EXPERIMENTAL; Interventions: Other: Point of care CD4+ after HIV diagnosis, Other: Accelerated ART initiation, Behavioral: SMS appointment reminders | Arm Label: Standard of care (SOC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Point of care CD4+ after HIV diagnosis; Assigned to Arm(s): Combination intervention + incentives, Combination intervention strategy(CIS) | Intervention Type: OTHER; Name: Accelerated ART initiation; Assigned to Arm(s): Combination intervention + incentives, Combination intervention strategy(CIS) | Intervention Type: BEHAVIORAL; Name: SMS appointment reminders; Assigned to Arm(s): Combination intervention + incentives, Combination intervention strategy(CIS) | Intervention Type: OTHER; Name: Non-cash Financial Incentives; Assigned to Arm(s): Combination intervention + incentives
C: Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy
D: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Arm Label: Same-day ART initiation with less frequent follow-up visits; Type: EXPERIMENTAL; Interventions: Other: Same-day ART initiation | Intervention Type: OTHER; Name: Same-day ART initiation; Assigned to Arm(s): Same-day ART initiation with less frequent follow-up visits | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Elective Induction of Nulliparous Labor: A Randomized Clinical Trial
Brief Summary: Primary outcome: to evaluate the effect of elective induction of labor (IOL), at 39 weeks gestation, on cesarean delivery rates in nulliparous women compared to expectant management (EM).

Secondary outcomes: to evaluate differences in the mean number of clinic visits/antepartum tests avoided with IOL, to compare the differences in utilization of inpatient resources (mean duration of inpatient stay, mean duration of labor), and to evaluate the effect of IOL on the risk of urinary/anal incontinence and sexual dysfunction as analyzed using previously validated measurements. We will evaluate differences in the rate of cervical change once active labor is diagnosed, and the time from completion of active labor, defined as complete dilation and complete effacement, to the delivery of fetus (definition of second stage of active labor). Furthermore, other secondary outcomes to be evaluated include comparisons between IOL and EM in regards to the occurence of chorioamnionitis, stillbirth, operative vaginal delivery, and meconium stained amniotic fluid. An evaluation of the predictive value of cervical length and Bishop score for vaginal delivery will also be examined.


Options:
A: Arm Label: Mechanical cervical ripening; Type: EXPERIMENTAL; Interventions: Device: Mechanical cervical ripening | Arm Label: Pharmacological cervical ripening; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pharmacological cervical ripening | Intervention Type: DEVICE; Name: Mechanical cervical ripening; Assigned to Arm(s): Mechanical cervical ripening | Intervention Type: DRUG; Name: Pharmacological cervical ripening; Assigned to Arm(s): Pharmacological cervical ripening
B: Intervention Type: DEVICE; Name: Transcervical Foley Catheter; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Transcervical Foley Catheter with an EASI; Assigned to Arm(s): N/A
C: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Foley Catheter and Oxytocin; Type: EXPERIMENTAL; Interventions: Device: Foley Catheter, Drug: Oxytocin | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter and Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Foley Catheter and Oxytocin, Oxytocin
D: Arm Label: Expectant management (EM) arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induction of Labor (IOL) arm; Type: EXPERIMENTAL; Interventions: Procedure: Induction of Labor | Intervention Type: PROCEDURE; Name: Induction of Labor; Assigned to Arm(s): Induction of Labor (IOL) arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage: Evidence of Kinematic Study
Brief Summary: This research centers on the comparison of the immediate efficacy (right after therapy) and the maintained efficacy (3 months and 6 months) between "Modified Constraint-Induced Movement Therapy" (mCIMT) group and control group at different age.


Options:
A: Arm Label: Real rTMS combined with CIT; Type: EXPERIMENTAL; Interventions: Device: real rTMS combined with constraint induced therapy | Arm Label: Sham rTMS combined with CIT; Type: SHAM_COMPARATOR; Interventions: Device: sham rTMS combined with constraint induced therapy | Intervention Type: DEVICE; Name: real rTMS combined with constraint induced therapy; Assigned to Arm(s): Real rTMS combined with CIT | Intervention Type: DEVICE; Name: sham rTMS combined with constraint induced therapy; Assigned to Arm(s): Sham rTMS combined with CIT
B: Intervention Type: BEHAVIORAL; Name: Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Pediatric Constraint-Induced Movement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Conventional pediatric motor rehabilitation therapy; Assigned to Arm(s): N/A
D: Arm Label: Constraint-induced Movement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Arm Label: Transditional rehabilitation; Type: OTHER; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Intervention Type: BEHAVIORAL; Name: Modified Constraint-induced Movement Therapy; Assigned to Arm(s): Constraint-induced Movement Therapy, Transditional rehabilitation

Answer: D